BridgeBio Pharma
BBIO
129 hedge funds and large institutions have $4.39B invested in BridgeBio Pharma in 2020 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 36 increasing their positions, 48 reducing their positions, and 13 closing their positions.
100% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 13
57% more call options, than puts
Call options by funds: $2.89M | Put options by funds: $1.83M
15% more capital invested
Capital invested by funds: $3.82B → $4.39B (+$569M)
13% more funds holding in top 10
Funds holding in top 10: 8 → 9 (+1)
11% more funds holding
Funds holding: 116 → 129 (+13)
0.34% less ownership
Funds ownership: 96.65% → 96.31% (-0.34%)
25% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 48
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$17.7M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$16M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$14.2M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$13.4M |
| 5 |
JP Morgan Chase
New York
|
+$8.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$26.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$16.5M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$10.2M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$9.94M |
| 5 |
CCM
CAAS Capital Management
New York
|
-$6.89M |
BBIO Hedge Fund Activity: Q3 2020 in Review
129 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Pharma (BBIO) for Q3 2020, worth a combined $4.39B — up 15% from $3.82B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new BBIO positions and 13 closed out — a net gain of 13 holders — while 36 added to existing stakes and 48 trimmed.
The largest buyer was BlackRock, adding an estimated $17.7M. The largest seller was State Street, cutting an estimated $26.2M.
- 129 institutional investors held BridgeBio Pharma (BBIO) as of Q3 2020, up from 116 in Q2 2020.
- Funds reported $4.39B of BridgeBio Pharma stock for Q3 2020, up 15% quarter-over-quarter.
- 26 funds opened new BridgeBio Pharma positions in Q3 2020 and 13 closed out, a net change of +13 holders.
- The largest BridgeBio Pharma buyer in Q3 2020 was BlackRock, an estimated $17.7M added.
- The largest BridgeBio Pharma seller in Q3 2020 was State Street, an estimated $26.2M sold.
Based on aggregated 13F filings for Q3 2020.